Company Profile

Accuronix Therapeutics Inc
Profile last edited on: 5/4/2020      CAGE: 7PA66      UEI: SFLBHKQFAN41

Business Identifier: Novel therapies selectively target cells and deliver cytotoxic payloads: increasing efficacy and reducing toxicity risk
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

20 South Sarah Street
Saint Louis, MO 63108
   (636) 346-3140
Location: Single
Congr. District: 01
County: St. Louis city

Public Profile

Two of the principals of Accuronix Therapeutics for over a decade have collaborated to extend the discoveries of one of them in the arena of the ?-2 receptor in cancer cells into the development of novel therapeutic modalities for pancreatic adenocarcinoma and a wide range of other tumor types. With an initial focus in pancreatic cancer, the Company’s mission is to develop novel oncology therapies based on technology that selectively targets ?-2 receptors overexpressed on cancer cells - applying a novel drug-targeting technology to some of the most difficult problems in cancer therapy

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2022 2 NIH $2,254,193
Project Title: Advancement of ACXT-3102 for the Treatment of Pancreatic Adenocarcinoma (PDAC)

Key People / Management

  Bradley T Keller -- CEO

  Dennis Schafer -- President and CEO

  Judy Ballard

  William Hawkins -- Founder

  Linda Law -- VP Clinical Development and CMO

  Robert Mach -- Founder

  Dirk M Spitzer

Company News

There are no news available.